Biotricity (NASDAQ: BTCY) Well Positioned With Impressive Revenue Growth and Near-Term Catalysts

Biotricity (BTCY) Could Be a Case Study for a Well Managed Businesses with Their Rapid Growth, Controlled Costs and a New Non-Dilutive Financing Deal
Good day everyone and welcome to all of our new group members,
As I said earlier, this is fast becoming one of my favorite Biotech companies to report on.
Biotricity, Inc. (NASDAQ: BTCY), is a medical diagnostic and consumer healthcare technology company.
Current price $4.315/share (at 10:30 a.m. EST 12-27-21)
In news released Monday morning the company announced a $12M non-dilutive debt financing. The company indicates the deal strengthens its balance sheet and positions the company for multiple new product launches in 2022. BTCY shares gained on the news.
Net proceeds of $10.18 million were received by the Company, after giving effect to the payment of $274,000 in origination and the repayment of approximately $1.57 million in prior Company indebtedness. In addition, the Company issued the Lender 57,536 warrants convertible into one share of common stock each, with a 7-year term and an exercise price of $6.26.
We last reported on BTCY seven weeks ago and wanted to update that report. I feel there is untapped value in this company and that the near-term prospects look good.
Outstanding shares 47.66M
Shares in float 37.45M
Revenues (ttm) $5.76M
Insider ownership 11.3%
The one metric that impresses me the most at BTCY is their revenue growth because growing revenues can remedy almost all financial metric concerns in the long haul. BTCY has a FYE of March 31st, so they have completed their FYE 22H1 and are coming to the end of Q3. Let’s look at their revenue growth:
FYE 3-31-19 $398K
FYE 3-31-20 $1.4M (+260% YoY)
FYE 3-31-21 $3.3M (+240% YoY)
FYE 3-31-22 H1 $3.5M (surpassed last year’s revenues already)
Earlier I said that BTCY was professionally managed, and I think that, because over the last three fiscal quarters, revenues have grown 80% from $1.0M to $1.8M but operating expenses have only grown by 52% from $3.6M to $6.3M. Additionally, BTCY is operating with an enviable 66% gross margin (FYE 22H1). Management must keep their “eye on the ball” to keep those figures consistent.
Growing revenues at a rapid pace is a challenge for any business at the onset of their growth, but growing revenues and maintaining a high gross margin while keeping expenses in check takes a real team of pros.
Earlier this month Dr. Waqaas Al-Siddiq, CEO addressed a letter to shareholders, and I urge you to review it as a part of your due diligence. I am going to unwrap some of the points made in that letter in our forthcoming full report.
Unique Selling Propositions (USPs) at BTCY
Many companies are competing in the home use cardiac device market, but BTCY is the one making their products capable of transmitting data to physicians, disrupting, and reducing the need for clinic-based treatment.
BTCY is creating an ecosystem with their product line where all their devices are working in tandem and transmitting data into their unique cloud system. Maybe they took a cue from Apple, a company that does the same thing with their products.
BTCY home use products are affordable. You can but their new, blockbuster product Bioheart on Amazon for $149.00.
The company has a unique selling approach with their flagship product, BioFlux, marketed to cardiac physicians. Not only does the company train doctors and staff on how to use the product, but they also train them on how to bill insurance companies with simple codes. This billing aspect of Biotricity products starts at the design stage. Smart!
With a proforma level of revenues for FYE 2022 looking to reach $10M, and a list of USPs to be envied, BTCY is one of the most exciting biotech companies we’ve reported on. We expect there could be continuous growth in the company value in the near and mid-term.
Stay tuned for our full report on BTCY where we discuss the near-term future of the company.
The Traders News Group
Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell your information to anyone. Please see our cookie policy below.

Cookie Policy (US)

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy Policy

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.

Editor@TradersNewsSource.com

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty thousand dollars cash via bank wire for our distributed opinions on btcy this week. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.

TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.